Quantcast

Latest Term of patent Stories

2014-10-07 08:29:48

SAN DIEGO, Oct. 7, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced the issuance of U.S. Patent No. 8,846,034 claiming methods for selecting a subject for treatment of a hyaluronan-associated disease with an anti-hyaluronan agent, such as PEGPH20, as well as diagnostic agents for the detection and quantification of hyaluronan in a biological sample in patients. Combinations and kits for use in practicing the methods are also provided. PEGPH20 is an...

2014-09-22 08:27:36

Company Continues to Bolster Intellectual Property Asset Portfolio and Provides Update on Litigation in Progress BETHESDA, Md., Sept. 22, 2014 /PRNewswire/ -- Spherix Incorporated (SPEX) -- an intellectual property development company committed to the fostering and monetization of intellectual property, today announced that the United States Patent & Trademark Office (USPTO) issued a new patent to the Company in the month of September that is part of a standard essential family of...

2014-09-17 08:29:00

Patents granted by the United States Patent and Trademark Office and European Patent Office and a notice of allowance from the Japanese Patent Office broaden the breadth of the Company's delivery technology platform MARLBOROUGH, Mass., Sept. 17, 2014 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies,...

2014-09-03 08:33:48

-- Brings Total Number of DelMar's Patents Covering VAL-083 to Two U.S. Patents and One International Patent -- VANCOUVER, British Columbia and MENLO PARK, Calif., Sept. 3, 2014 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar") today announced that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for patent application number 13/933,751, covering improved methods for synthesizing VAL-083, DelMar's lead drug candidate, which is...

2014-08-11 08:34:25

Includes Recent Corporate Activities and Events NEW YORK, Aug. 11, 2014 /PRNewswire/ -- Finjan Holdings, Inc. (NASDAQ: FNJN), a technology company committed to enabling innovation through the licensing of its intellectual property, today is providing an update on the Company's continued progress in executing its strategy. Through our wholly-owned subsidiary Finjan Inc., we own a portfolio of patents related to security software that proactively detects malicious code and thereby protects end...

2014-07-31 16:26:46

Total of 10 Patents Issued to the Company in 45 Days CAMPBELL, Calif., July 31, 2014 /PRNewswire/ -- hopTo Inc. (OTCQB: HPTO) developer of one of the most comprehensive mobile productivity workspaces available, today announced that the U.S. Patent and Trademark Office granted hopTo, Inc. 10 additional patents, bringing the total number of patents granted and allowed to 18. hopTo Inc. now has a comprehensive patent portfolio of 170 total applications in more than 75 unique patent families....

2014-07-30 23:15:58

Genomics R&D firm, Ryogen LLC, received two U.S. Patents – its 31st and 32nd – that are directed to polynucleotide sequences that play critical roles in various cancers. Suffern, N.Y. (PRWEB) July 30, 2014 Ryogen LLC, an R&D company focusing on polynucleotide sequences implicated in human diseases, was awarded two new patents this month, bringing the total number of its issued U.S. Patents to 32. U.S. Patent No. 8,765,928 entitled “Identification of isolated genomic...

2014-07-29 08:33:16

TAIPEI, July 29, 2014 /PRNewswire/ -- Apex Medical Corporation (Apex, TWSE: 4106), a leading player in the Respiratory Therapy and Pressure Area Care sectors, announces that it is appealing the judgment of the Regional Court of Munich in Germany that found the headgear of certain mask models infringe a ResMed patent. Apex notes that it has initiated invalidity challenges against various ResMed patents in major countries. Apex further reiterates its continuous efforts in...

2014-07-15 16:27:40

-- Patent Covers Composition of Matter for APD371 and Related Compounds -- SAN DIEGO, July 15, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that it was granted U.S. Patent No. 8,778,950, entitled "Cannabinoid Receptor Modulators," by the United States Patent and Trademark Office for APD371, an agonist of the cannabinoid receptor 2 (CB2). Arena is exploring several potential indications for APD371, including chronic pain, and is currently conducting...

2014-06-03 08:39:47

ObjectVideo's '923 Patent successfully emerges from Patent Office Reexamination; First of two seminal ObjectVideo metadata patents in Reexam to pass review. RESTON, Va., June 3, 2014 /PRNewswire/ -- ObjectVideo, Inc., a leading provider of video analytics solutions, announced today that the first of two of its seminal metadata patents undergoing Reexamination successfully emerged after review by the U.S. Patent & Trademark Office ("USPTO")....


Word of the Day
negawatt
  • A unit of saved energy.
Coined by Amory Lovins, chairman of the Rocky Mountain Institute as a contraction of negative watt on the model of similar compounds like megawatt.